TPMT and acute lymphoblastic leukemia: Another relevant study has considered the role of genetic determinants of mercaptopurine toxicity during consolidation therapy, together with SLCO1B1: this study on adverse effects considered 189 children with ALL and evaluated the association between genetic determinants of TPMT activity in patients and the incidence of severe GI toxicity.